Abstract:This is a very special issue of the Asian Journal of Andrology (AJA), which has recently become a part of the Nature Publishing Group's stable.Prostate cancer is unquestionably the most controversial of all the solid malignancies, and we were both proud to be asked to serve as guest editors for this one-off publication.Accordingly, we have commissioned reviews from some of the best researchers and most experienced clinicians and combined these with state-of-the-art research papers.Prostate cancer is best regarded as a continuum, from the earliest microfoci of malignancy to hormone-relapsed disease, and in this special issue we have tried to cover as many aspects as possible of this progressive disease.This editorial aims to set the scene and introduce a complex subject that is examined in far greater detail in the commissioned reviews and original papers that follow.Worldwide, prostate cancer is the most commonly diagnosed malignancy to afflict men beyond middle age, and is second only to lung cancer as a cause of cancer deaths.Although the incidence continues to rise worldwide, mortality from prostate cancer in the USA recently reached a plateau and has started to decline, but at a rate four times faster than that in the UK [1].Some have attributed this drop to the efforts made in North America to detect prostate cancer early, although other factors, including more effective treatment, may also have contributed.Although the incidence of prostate cancer is lower in Asian countries than that in the West, the incidence in the East is rapidly rising.Take Shanghai in China as an example; it is very worrying that the average annual incidence of prostate cancer rose from 1.833/10 6 in 1984-1989 to 9.59/10 6 in 2005 [2,3].Age is the strongest risk factor for prostate cancer, but a family history of the disease affecting one or more firstdegree relatives increases risk by around 2.8 times.Obesity and a Western-style diet high in saturated fats are significant risk factors for the development of prostate cancer.The very latest information on the genetic basis of prostate cancer is reported in the review by Guy et al. [4] in this issue.A large number of studies have evaluated the effects of diet manipulation/supplementation or drug treatment to reduce the incidence of prostate cancer, but the evidence for their efficacy is still weak.The 5a-reductase inhibitor finasteride has been shown to reduce the incidence of prostate cancer by 24.8% compared with placebo over a 7-year period, although at the cost of a small incidence of sexual side effects and a possible increase in the Gleason pattern of the cancers diagnosed in the treated group [5].In general, the earlier prostate cancer is detected, the better the outlook for the patient in terms of cure or arresting cancer progression.An increasing majority of patients present simply with an isolated increase in prostate-specific antigen (PSA); however, there is no firm evidence that universal screening will reduce mortality, although trials are ongoing.The measurement of PSA, a glycoprotein responsible for liquefying semen, is currently the most effective single screening test for the early detection of prostate cancer.Approximately 25% of men with PSA levels above the normal range (≥ 4 ng mL -1 ) have prostate cancer, and the risk increases to more than 60% in men with PSA levels above 10 ng mL -1 .However, a recent study in prostate cancer prevention, in which all men in the placebo group received a biopsy, reported that the incidence of prostate cancer in men with PSA less than 4 ng/mL and normal results on digital rectal examination (DRE) was not inconsiderable [5].A particularly difficult clinical situation occurs when the PSA continues to rise in spite of a previous negative biopsy.A new molecular marker, known as PCA3, may be especially useful in this respect.A urine sample taken immediately after a prostatic massage is analysed.A value of greater than 35 indicates an increased risk that the prostate harbours a malignancy.Furthermore, this new marker may be useful in stratifying men with clinically significant tumours from those with low-risk cancers, which can be managed conservatively [6].As described here by Borley and Feneley [7], transrectal ultrasonography (TRUS) is the most commonly used modality to image the prostate gland and also to direct the prostate biopsy needle.Antibiotic treatment, usually with a quinolone such as ciprofloxacin, is given before and after the procedure to reduce the risk of infection, which is currently estimated at around 2%. Usually 8-14 TRUS-guided biopsies are taken from different regions of the prostate with an 18gauge needle.This procedure is now routinely performed on an outpatient basis, preferably after infiltration with local anaesthesia.Histological analysis confirms the presence or absence of cancer and provides a so-called Gleason score for each core.The higher the Gleason score, the greater the risk of disease progression and metastasis.Magnetic resonance imaging (MRI) is widely used to stage prostate cancer locally and to diagnose or exclude lymph node metastases.Promising results have been reported with the use of ultra-small super-paramagnetic iron oxide particles as an aid to nodal metastasis evaluation by MRI.The addition of magnetic resonance (MR) spectroscopy (evaluation of

Unexpectedly high variability in determining tumour extent in prostatic biopsies: implications for active surveillance

Indications, Strategies, and Development on Prostate Targeted Biopsy: Report of the Panjiayuan Consensus Conference 2022

Interassay Variability and Clinical Implications of Five Different Prostate-specific Antigen Assays

Current status of prostate biopsy in Chinese Prostate Cancer Consortium member hospitals

Systematic Biopsy vs. Prostatectomy: Evaluating Correlations and Grading Discrepancies in Prostate Cancer

Active surveillance for low-risk prostate cancer with high tumor burden at biopsy: lessons learned from a contemporary radical prostatectomy cohort

Topline/Final Diagnostic Inclusion of Relevant Histologic Findings in Surgical Pathology Reporting of Carcinoma in Prostate Biopsies

Key learnings from concordant systematic biopsies in prostate‐specific membrane antigen positron emission tomography/computed tomography‐guided prostate biopsies: Enhancing targeting accuracy

Identifying patient profiles and mapping the patient journey across three countries in a large-scale, fully digital survey of patients with prostate cancer.

Exploration on Gleason Score Variation Trend of Patients with Prostate Carcinoma from 1996 to 2019: a Retrospective Single Center Study

Quantification of Gleason Pattern 4 Metrics Identifies Pathologic Progression in Patients With Grade Group 2 Prostate Cancer on Active Surveillance

Accuracy of gross tumour volume delineation with [68Ga]-PSMA-PET compared to histopathology for high-risk prostate cancer

Quantification and predictors of prostate position variability in 50 patients evaluated with multiple CT scans during conformal radiotherapy

Physician Perception of Grade Group 1 Prostate Cancer

Spatial Transcriptomic Analysis of Virtual Prostate Biopsy Reveals Confounding Effect of Heterogeneity on Genomic Signature Scoring

Heterogeneity in Genomic Risk Assessment from Tissue Based Prognostic Signatures Used in the Biopsy Setting and the Impact of Magnetic Resonance Imaging Targeted Biopsy

Adverse Pathology after Radical Prostatectomy of Patients Eligible for Active Surveillance-A Summary 7 Years after Introducing mpMRI-Guided Biopsy in a Real-World Setting

Accuracy of MRI-ultrasound fusion-guided and systematic biopsy of the prostate

Editorial and Introduction to Asian Journal of Andrology Prostate Cancer Special Issue

Preliminary Study on Ultrasound-Guided Prostate Biopsy Specimen Scores.

Abstract B129: Clinical implications of inter- and intra- prostatic heterogeneity.